

PATHOZYME[®] CARCINOEMBRYONIC ANTIGEN Ref OD317

Enzyme-Immunoassay (EIA) for the Quantitative Determination of CEA

In human serum

Store at 2°C to 8°C. DO NOT FREEZE

For in-vitro diagnostic use only.

INTRODUCTION

Carcinoembryonic antigen is an oncofoetal antigen. It is a glycoprotein and has a molecular weight of 200000 Da. Elevated serum CEA has been associated with many cancers, including lung, liver, pancreas, breast, colon, prostate, stomach and ovary. With several of these conditions it is recommended that serum CEA measurements be made in conjunction with the more traditional tumour markers.

In cases of colon cancer 80% of patients had elevated serum CEA levels. However this blood test must be used in conjunction with all clinical evidence as benign conditions can also cause slightly elevated CEA, such as liver disease. In lung cancer CEA levels are elevated in 67% of non-small cell lung cancer cases and 33% of small cell lung cancer cases.

In malignant disease the serum CEA levels have been directly related to the stage and extent of the disease. Therefore CEA is very useful in monitoring the course of treatment for cancer patients. Recently it has been stated that CEA is the best non-invasive tool for monitoring patients with colorectal cancer. The pre-operative CEA level also has good prognostic value in cancers of the breast and colon; high pre-operative CEA levels, poor prognosis.

INTENDED USE

PATHOZYME CEA is an Enzyme Immunoassay (EIA) for the quantitative determination of Carcinoembryonic Antigen (CEA) in human serum.

For professional use only.

PRINCIPLE OF THE TEST

Specific monoclonal, anti-CEA antibodies are coated onto microtitration wells. Test sera are applied. Then monoclonal anti-CEA labelled with Horseradish Peroxidase enzyme (Conjugate) is added. If human CEA is present in the sample, it will combine with the antibody on the well and the enzyme Conjugate, resulting in the CEA molecules being "sandwiched" between the solid phase and the enzyme linked antibodies. After incubation, the wells are washed with distilled water to remove unbound labelled antibodies. On addition of the Substrate (TMB), a colour will develop only in those wells in which enzyme is present, indicating the presence of CEA. The enzyme reaction is stopped by the addition of dilute Hydrochloric Acid and the absorbance is then measured at 450nm. The concentration of CEA is directly proportional to the colour intensity of the test sample.

This test has been calibrated against in house standards. There is no International standard for this test.

Ref
OD317



CONTENTS

Microtitre Plate

Breakable wells coated with specific antibody contained in a resealable foil bag with a desiccant.

Cal A 0 ng/ml

Reference Standard: Human serum free of CEA. Ready to use. (Colourless)

Cal B 3 ng/ml

Reference Standard: CEA diluted in human serum. Ready to use. (Colourless)

Cal C 12 ng/ml

Reference Standard: CEA diluted in human serum. Ready to use. (Colourless)

Cal D 30 ng/ml

Reference Standard: CEA diluted in human serum. Ready to use. (Colourless)

Cal E 60 ng/ml

Reference Standard: CEA diluted in human serum. Ready to use. (Colourless)

Cal F 120 ng/ml

Reference Standard: CEA diluted in human serum. Ready to use. (Colourless)

Conj

Anti-CEA HRP Conjugate: Anti-CEA conjugated to HRP. Ready to use (Pink)

12 x 8 wells x 1

1 ml

1 ml

1 ml

1 ml

1 ml

1 ml

11 ml

Subs	TMB	11 ml		
Substrate Solution: 3,3', 5,5' Tetramethyl Benzidine in a citrate buffer. Ready to use. (Colourless)				
Soln	Stop	HCl	1M	11 ml
Stop Solution: Hydrochloric Acid diluted in purified water. Ready to use. (Colourless)				
Instruction Leaflet and EIA Data Recording Sheet				1 + 1

MATERIAL REQUIRED BUT NOT PROVIDED

Micropipettes: 100µl, 200µl, 1000µl and 5000µl
Disposable pipette tips
Absorbent paper
Microplate reader fitted with a 450nm filter
Graph paper
Thoroughly clean laboratory glassware.

PRECAUTIONS

PATHOZYME CEA contains materials of human origin which have been tested and confirmed negative for HCV, HIV I and II antibodies and HBsAg by approved procedures at single donor level. Because no test can offer complete assurance that products derived from human source will not transmit infectious agents it is recommended that the reagents within this kit be handled with due care and attention during use and disposal. All reagents should, however, be treated as potential Biohazards in use and for disposal. Do not ingest

PATHOZYME CEA reagents do not contain dangerous substances as defined by current UK Chemicals (Hazardous Information and Packaging for Supply) regulations. All reagents should, however, be treated as potential biohazards in use and disposal. Final disposal must be in accordance with local legislation.

PATHOZYME CEA Stop Solution is dilute Hydrochloric Acid and is therefore corrosive. Handle with care. In case of contact, rinse thoroughly with water.

PATHOZYME CEA contain 1% Proclin™ 300* as a preservative which may be toxic if ingested. In case of contact, rinse thoroughly with running water and seek medical advice.

*Proclin™ 300 is a trade mark of ROHM & HAAS Limited.

STORAGE

Reagents must be stored at temperatures between 2°C to 8°C.

Expiry date is the last day of the month on the bottle and the kit label. The kit will perform within specification until the stated expiry date as determined from date of product manufacture and stated on kit and components. Do not use reagents after the expiry date.

Exposure of reagents to excessive temperatures should be avoided. Do not expose to direct sunlight.

DO NOT FREEZE ANY OF THE REAGENTS (except for standard storage) as this will cause irreversible damage.

SPECIMEN COLLECTION AND PREPARATION

Obtain a sample of venous blood from the patient and allow a clot to form and retract. Centrifuge clotted blood sample and collect clear serum. Fresh serum samples are required.

Do not use haemolysed, contaminated or lipaemic serum for testing as this will adversely affect the results.

Serum may be stored at 2°C to 8°C for up to 48 hours prior to testing. If longer storage is required, store at -20°C for up to 1 year. Thawed samples must be mixed prior to testing.

Do not use Sodium Azide as a preservative as this may inhibit the Peroxidase enzyme system.

Do not repeatedly freeze-thaw the specimens as this will cause false results.

REAGENT PREPARATION

All reagents should be brought to room temperature (20°C to 25°C) and mixed gently prior to use. Do not induce foaming.

LIMITATIONS OF USE

The use of samples other than serum has not been validated in this test. There is no reuse protocol for this product. When making an interpretation of the test it is strongly advised to take all clinical data into consideration. Diagnosis should not be made solely on the findings of one clinical assay.

ASSAY PROCEDURE

1. Bring all the kit components and the test serum to room temperature (20°C to 25°C) prior to the start of the assay.
2. One set of Standards should be run with each batch of test serum. Secure the desired number of coated wells in the holder. Record the position of the standards and the test serum on the EIA Data Recording Sheet provided.
3. Unused strips should be resealed in the foil bag containing the desiccant, using the resealing zip-lock before being replaced at 2°C to 8°C.
4. Dispense 50µl of Standards and test serum into the assigned wells.
5. Dispense 100µl of Anti-CEA HRP Conjugate into each well.
6. Thoroughly Mix for 30 seconds. It is very important to mix completely at this stage.
7. Incubate the plate for 60 minutes at room temperature (20°C to 25°C).
8. At the end of the incubation period, discard the contents of the wells by flicking plate contents into a Biohazard container. Then strike the wells sharply against absorbent paper. Ensure adequate disinfectant is contained in the Biohazard container.
9. Hand Washing: Fill the wells with a minimum of 300µl of distilled water per well. Flick plate contents into a Biohazard container. Then strike the wells sharply against absorbent paper. Wash the empty wells 5 times.
10. Strike the wells sharply onto absorbent paper or paper towel to remove all residual water droplets.
11. Machine Washing: Ensure that 300µl of distilled water is dispensed per well and that an appropriate disinfectant is added to the waste collection bottle. Wash the empty wells 5 times. After washing remove excess fluid by striking the wells sharply onto absorbent paper or paper towel to remove all residual water droplets.
12. Dispense 100µl Substrate Solution into each well and mix gently for 5 seconds.
13. Incubate in the dark for 20 minutes at room temperature (20°C to 25°C).
14. Stop the reaction by adding 100µl Stop Solution to each well.
15. Gently mix for 30 seconds to ensure that the blue colour changes completely to yellow colour.
16. Read the optical density immediately (no later than 10 minutes) using a microplate reader with a 450nm filter.

TROUBLESHOOTING

For use by operatives with at least a minimum of basic laboratory training.

Do not use damaged or contaminated kit components.

Use a separate disposable tip for each sample to prevent cross contamination.

Duplication of all standards and specimens, although not required, is recommended.

Specimens and standards should be run at the same time to keep testing conditions the same.

It is recommended that no more than 32 wells be used for each assay run if manual pipetting is used, since pipetting of all Standards and specimens should be completed within 3 minutes. A full plate of 96 wells may be used if automated pipetting is available.

Replace caps on all reagents immediately after use.

Avoid repeated pipetting from stock reagents as this is likely to cause contamination.

Do not mix reagents or antibody coated strips from different kits. When dispensing, care should be taken not to touch the surface of the well.

Do not allow reagent to run down the sides of the well. Prior to the start of the assay bring all reagents to room temperature (20°C to 25°C). Gently mix all reagents by gentle inversion or swirling.

Once an assay has been initiated, the wells should not be allowed to become dry during the assay.

Do not contaminate the Substrate Solution as this will render the whole kit inoperative.

Check the precision and accuracy of the laboratory equipment used during the procedure to ensure reproducible results.

The unused strips should be resealed in the foil bag, containing the desiccant, using the resealing zip-lock before being replaced at 2°C to 8°C.

CALCULATION OF RESULTS

The graph produced by the Calibrators should be Hyperbolic in shape with the OD450 of the Calibrators proportional to their concentration. The OD of Calibrator A should be less than 0.75 and the OD of Calibrator F should be greater than 1.5 for the assay results to be valid. Calculate the mean absorbance value (A450) for each set of Standards and specimens. Construct a standard curve by plotting the mean absorbance from each Standard against its concentration in ng/ml on graph paper. Use the mean absorbance values for each specimen to determine the corresponding concentration of CEA in ng/ml from the standard curve. If levels of controls or users known samples do not give expected results, test results must be considered invalid. If using a software package choose a quadratic regression curve fit.

EXPECTED VALUES AND SENSITIVITY

The most complete study of CEA is a compilation of collaborative studies in which CEA values in 35,000 samples from more than 10,000 patients and controls were analysed. Of 1,425 normal persons who did not smoke, 98.7% had values less than 5.0 ng/ml. It is recommended that each laboratory establish its own normal range. The minimum detectable concentration of CEA by **PATHOZYME CEA** estimated to be 1.0 ng/ml.

EVALUATION DATA

Calibrated to major competitors and in house standards. The co-efficient of variation of **PATHOZYME CEA** is less than or equal to 10%.

In an evaluation between the Omega Pathozyme CEA kit and the Abbott AXSym CEA Kit for samples with levels between 0.2 and 50400 ng/ml the kits gave good correlation.

REFERENCES

- (1) **Gold, P., Freedman, S. O.** Demonstration of tumour specific antigen in human colonic carcinoma by immunologic tolerance and absorption techniques. *J. Exp. Med.* 1965;127:439-462.
- (2) **Thompson, D. P. M., Krupey, J., Freedman, S. O.** et al. The radioimmunoassay of circulating Carcinoembryonic antigen of the human digestive system. *Proc. Natl. Acad. Sci. USA* 1969;64:161-167.
- (3) **Schwartz, M. K.** Tumour Markers in diagnosis and screening, In Ting, S. W., Chen, J. S., Schwartz, M. K. (eds.). *Human Tumour Markers*. Amsterdam: Elsevier Science, 1987;3-16.
- (4) **Zamcheck, N. and Martin, E. W.** Sequential Carcinoembryonic Antigen levels in Pancreatic Cancer: Some Clinical Correlations. *Cancer*. 1981;47:1620-1627.
- (5) **Mughal, A. W., Hortobagyi, G. N., Fritsche, H. A., Buzdar, A. U., Yap, H-Y. and Blumenschein, G. R.** Serial Plasma Carcinoembryonic Antigen Measurements During Treatment of Metastatic Breast Cancer. *JAMA*. 1983;259:1881-1886.

QUICK REFERENCE TEST PROCEDURE

1. Dispense 50 μ l of Standards or Test Serum and 100 μ l of Anti-CEA HRP Conjugate into each well and mix thoroughly for 30 seconds.
2. Incubate for 60 minutes at room temperature (20°C to 25°C).
3. Discard well contents and wash five times with distilled water.
4. Add 100 μ l Substrate Solution into each well and gently shake for 5 seconds.
5. Incubate in the dark for 20 minutes at room temperature (20°C to 25°C).
6. Add 100 μ l of Stop Solution to each well and gently shake for 30 seconds.
7. Read the Optical Densities immediately (no later than 10 minutes) using microplate reader with a 450nm filter.

8081 ISSUE 5 Revised April 2010
© Omega Diagnostics Ltd 2010



OMEGA DIAGNOSTICS LTD.
Omega House, Hillfoots Business Village
Alva FK12 5DQ, Scotland, United Kingdom
odl@omegadiagnostics.co.uk
www.omegadiagnostics.com
AN ISO 9001 AND ISO 13485 CERTIFIED COMPANY